=> s 107215-91-8/rn
L2 1 107215-91-8/RN

=> d l2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1998 ACS

RN ***107215-91-8*** REGISTRY
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-(hydroxymethyl)-7-.beta.-D-ribofuranosyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H16 N4 O6
SR CA
LC STN Files: CA, CAPLUS



TI 5-Decarboxy-5-formylcadeguomycin analogs
ACCESSION NUMBER: 1987:176807 CAPLUS
DOCUMENT NUMBER: 106:176807
TITLE: 5-Decarboxy-5-formylcadeguomycin analogs
INVENTOR(S): Okamoto, Kaoru; Goto, Toshio; Tanaka, Nobuo
PATENT ASSIGNEE(S): Nippon Zoki Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF

	NUMBER	DATE
PATENT INFORMATION:	JP 61229897 A2	861014 Showa
APPLICATION INFORMATION:	JP 85-73256	850405

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
GI Diagram(s) available in offline prints and/or printed CA Issue.
AB The title compd. (I; R = CHO; R1-R5 = X = H), useful as an anticancer agent, was prepd. Thus, hydrogenolysis of D-ribo-I (R = CH2OH, R1 = CH2OMe, R2 = R5 = Ac, R3R4 = Me2C, X = Br) in aq. MeOH contg. AcOK over Pd/C, oxidn. of the resulting D-ribo-I (X = H) in MeCN with MnO2 for 1/2 h followed by ammonolysis and hydrolysis with aq. CF3CO2H at 70.degree. for 1 h gave D-ribo-I (R = CHO, R1-R5 = X = H). This at 10 .mu.g/mL in vitro inhibited by 50% the growth of mouse lymphatic leukemia L5178Y cells and in vitro enhanced the incorporation of 3H-thymidine into human leukemia K562 cells. Tablets and capsules contg. the title compds. were prepd.

TI 5-Decarboxy-5-formylcadeguomycin analogs

ACCESSION NUMBER:	1987:176807 CAPLUS	
DOCUMENT NUMBER:	106:176807	
TITLE:	5-Decarboxy-5-formylcadeguomycin analogs	
INVENTOR(S):	Okamoto, Kaoru; Goto, Toshio; Tanaka, Nobuo	
PATENT ASSIGNEE(S):	Nippon Zoki Pharmaceutical Co., Ltd., Japan	
SOURCE:	Jpn. Kokai Tokkyo Koho, 12 pp.	
	CODEN: JKXXAF	
	NUMBER	DATE
PATENT INFORMATION:	JP 61229897 A2	861014 Showa
APPLICATION INFORMATION:	JP 85-73256	850405
DOCUMENT TYPE:	Patent	
LANGUAGE:	Japanese	

GI



I

AB The title compd. (I; R = CHO; R1-R5 = X = H), useful as an anticancer agent, was prepd. Thus, hydrogenolysis of D-ribo-I (R = CH2OH, R1 = CH2OMe, R2 = R5 = Ac, R3R4 = Me2C, X = Br) in aq. MeOH contg. AcOK over Pd/C, oxidn. of the resulting D-ribo-I (X = H) in MeCN with MnO2 for 1/2 h followed by ammonolysis and hydrolysis with aq. CF3CO2H at 70.degree. for 1 h gave D-ribo-I (R = CHO, R1-R5 = X = H). This at 10 .mu.g/mL in vitro inhibited by 50% the growth of mouse lymphatic leukemia L5178Y cells and in vitro enhanced the incorporation of 3H-thymidine into human leukemia K562 cells.